<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ABBOTT LABORATORIES' 1999 THIRD QUARTER FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q FILING. </LEGEND> <MULTIPLIER> 1,000 <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> JAN-01-1999 <PERIOD-END> SEP-30-1999 <CASH> 531,070 <SECURITIES> 99,310 <RECEIVABLES> 2,068,985 <ALLOWANCES> 185,487 <INVENTORY> 1,417,305 <CURRENT-ASSETS> 5,878,049 <PP&E> 9,654,073 <DEPRECIATION> 4,937,539 <TOTAL-ASSETS> 13,574,225 <CURRENT-LIABILITIES> 4,329,007 <BONDS> 1,336,425 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 1,516,933 <OTHER-SE> 5,152,720 <TOTAL-LIABILITY-AND-EQUITY> 13,574,225 <SALES> 9,662,859 <TOTAL-REVENUES> 9,662,859 <CGS> 4,444,416 <TOTAL-COSTS> 4,444,416 <OTHER-EXPENSES> 858,361<F1> <LOSS-PROVISION> 10,401 <INTEREST-EXPENSE> 111,842 <INCOME-PRETAX> 2,465,772 <INCOME-TAX> 690,416 <INCOME-CONTINUING> 1,775,356 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 1,775,356 <EPS-BASIC> 1.17 <EPS-DILUTED> 1.15 <FN> <F1>Other expenses consist of research and development expenses. </FN>